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group, of which 12 were men. The mean age of the patients was 65 years in the cisapride group and 67 years in the control group.
Study design
This was a randomised, double-blinded, clinical trial carried out in a single centre. The patients were randomised using a sealed envelope assignment. The nursing and physician staff were blinded to the patient allocation. The patients were not followed after discharge.
Analysis of effectiveness
All patients included in the study were accounted for in the analysis. The primary health outcomes assessed in the analysis were: length of hospital stay; adjusted length of hospital stay, defined as the period of time at which the patient is tolerating a regular diet, having bowel movements, and would otherwise be discharged if not for a separate cause unrelated to bowel motility; post-operative days to first bowel movement and regular diet intake; and peri-operative complications.
The study groups were comparable in terms of their demographics and medical characteristics.
Effectiveness results
The mean length of hospital stay was 5.5 (+/-1.4) days in the study group and 6.7 (+/-2.1) days in the control group, (p=0.06).
The mean adjusted length of hospital stay was 5.1 (+/-1.0) days in the study group and 6.3 (+/-1.5) days in the control group, (p=0.006).
The mean post-operative days to first bowel movement were 3.7 (+/-0.7) days in the study group and 4.8 (+/-1.2) days in the control group, (p<0.05).
The mean post-operative days to regular diet intake were 4.1 (+/-0.8) days in the study group and 4.9 (+/-1.1) days in the control group, (p<0.05).
A median one-day difference was found in all of these outcome measures.
There were 4 complications in the study group and 3 complications in the control group.
Clinical conclusions
The analysis of the effectiveness showed that cisapride significantly improved bowel motility, compared with placebo.
Measure of benefits used in the economic analysis
The health outcomes were left disaggregated and no summary benefit measure was used. A cost-consequences analysis was therefore carried out.
